Filing Flows

Filing Flows › Health Care › Perrigo (PRGO)

Perrigo (PRGO) earnings and revenue breakdown

Latest: Q3 2026 · 10-Q filed Nov 4, 2026 · Perrigo (PRGO) Q3 2026 earnings results →

Q3 2026 Revenue down 5% year over year to $989M · 3¢ of every $1 of revenue lost · operating margin 2.3%

Perrigo made $989M in Q3 2026 (-5% Y/Y). Operating margin 2.3%, net loss $27.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 4, 2026.

Revenue$989M
Year over year-5%
Operating margin2.3%
Net earnings−$27.5M
Operating cash flow$96.2M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $988.6M in Q3 2026, down 5% year over year and down 3% from the previous quarter.

Gross margin was 32.4%, down 3.7 points from Q3 2025. Operating profit was $23.1M, a 2.3% margin (down 4.6 points year over year). Operating expenses fell 2% while revenue fell 5%. The fastest-growing cost line was General & admin (+32%). The quarter ended with a net loss of $27.5M, after a profit of $74.5M the previous quarter. Net interest and other expense of $54.4M was the main reason.

Operating cash flow was $96.2M (up 86% year over year). Non-cash charges added back $81.8M of depreciation and amortization and $10.1M of share-based compensation. Working capital and other items added $31.8M. Capital expenditures of $17.5M left free cash flow of $78.7M.

Quarterly history

Perrigo revenue by quarterPerrigo revenue by quarter$1.0BQ1 2025$1.1BQ2 2025$1.0BQ3 2025$1.1BQ4 2025$969MQ1 2026$1.0BQ2 2026$989MQ3 2026
Perrigo net earnings by quarterPerrigo net earnings by quarter−$6.4MQ1 2025−$8.4MQ2 2025$7.5MQ3 2025−$1.4BQ4 2025−$399MQ1 2026$74.5MQ2 2026−$27.5MQ3 2026
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q3 202610-QNov 4, 2026$989M-5%2.3%−$27.5M$96.2M
Q2 202610-QAug 5, 2026$1.0B-3%2.3%$74.5M$82.6M
Q1 202610-QMay 6, 2026$969M-7%-38.4%−$399M−$114M
Q4 202510-KFeb 26, 2026$1.1B-2%-116.0%−$1.4B$175M
Q3 202510-QNov 5, 2025$1.0B-4%7.0%$7.5M$51.7M
Q2 202510-QAug 6, 2025$1.1B-0.9%4.3%−$8.4M$75.9M
Q1 202510-QMay 7, 2025$1.0B-4%4.5%−$6.4M−$64.5M

Charts

Perrigo: revenue growth, year over year and quarter over quarterPerrigo: revenue growth, year over year and quarter over quarterY/YQ/Q-4%Q1 2025-1%+1%Q2 2025-4%-1%Q3 2025-2%+6%Q4 2025-7%-13%Q1 2026-3%+6%Q2 2026-5%-3%Q3 2026
Latest (Q3 2026): Y/Y -5%, Q/Q -3%.
Perrigo: where the cash came from (+) and went (−), TTM to Q3 2026Perrigo: where the cash came from (+) and went (−), TTM to Q3 2026Asset & business sales$366MNet borrowing (+) / repaid (−)−$345MOperating cash flow$241MDividends−$160MCapital spending−$72.4MOther financing−$19.4MTaxes on employees’ shares−$7.7MExchange rates−$5.2MOther investing$5.0MCash drawn (+) / kept (−)−$2.2M
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Perrigo: profit against cash, quarter by quarterPerrigo: profit against cash, quarter by quarterNet incomeOperating cash flow−$44.5M$313MQ4 2024−$6.4M−$64.5MQ1 2025−$8.4M$75.9MQ2 2025$7.5M$51.7MQ3 2025−$1.4B$175MQ4 2025−$399M−$114MQ1 2026$74.5M$82.6MQ2 2026−$27.5M$96.2MQ3 2026
Latest (Q3 2026): Net income −$27.5M, Operating cash flow $96.2M.
Perrigo: diluted shares by fiscal yearPerrigo: diluted shares by fiscal year137MFY2020134MFY2021134MFY2022135MFY2023137MFY2024138MFY2025
+0.9% since FY2020: more shares outstanding (issuance, stock pay).
Perrigo: long-term debt falling due (FY2025)Perrigo: long-term debt falling due (FY2025)$36.6M2026$409M2027$12.1M2028$945M2029$752M2030$1.5BLater
Cash $532M, short-term investments —, long-term debt — at 2025-12-31.
Perrigo in its industry: growth against margin (225 companies, SIC 2834)Perrigo in its industry: growth against margin (225 companies, SIC 2834)revenue growth, year over year →↑ operating marginmedian +11%median -50%JNJLLYMRKABBVPFEBMYABTREGNTEVAVTRSVRTXBHCZTSONCOGNALNYELANJAZZBMRNAMRXUTHRRPRXNRIXINSMKeenova Therapeutics plcALKSMDGLPAHCSRPTPTCTINDVBBIOACADCORTPBHANIPKNSAPTGXHRMYIONSAXSMTGTXSUPNTVTXCOLLVREOFAMPHMIRMPCRXRARELQDAARQTIRWDARDXNATRXNCREBSZLABXERSINVACRMDMNKDRYTMURGNPHATAUPHSNDXRIGLLGNDEOLSARWRPGENHROWVNDAOPKSDGRGERNETONAGIOPBYITNGXCYRXCYTKMRVIORGONUVBLFVNSIGAKROSAMRNZVRASPRYHRTXAKBABCYCKPTIGYREMGNXELTPSEPNVRDNLFCRCrinetics Pharmaceuticals, Inc.VSTMKURATBPHLABADCTNAMSFBIOXLODERMARCTRMTIAYTUFHTXENTATNXPOCULASMBWVEAPMDBFRIABEOSTOKLXRXCAPRIDYANKTRZOMDFINBPJANXSBFMGOSSETSTRCUSCPIXLIFDCUEAQSTPRAXWHWKVERUEMMAGENBVRCACELUQUREZYMEEQABCLIMNMKYNBAKTSRNACVSICNTBTRAWISCOEVFMTVRDLPCNCAMPAtaiBeckley Inc.CTMXALMSPMHSACRSVTGNROIVKRROJAGXENSCKRSAABUSPRPHSTTKCPHITRDATXMDGOVXNWBOBIOEUPBIRDOVIDSPRBXBIOPRTAMCRBARVNMNOVSLNIGCBIOALGVNDNTHCPMDSPRORFLCOYASCYXBFRGSXTPBTAIQHCWBSERYARWRNACRGBPAVTXCLNNNTHIHINDAAGHALTONCOCRVOSKVIBOLTBDPTLYELIBOPULMPRGO (-5%, 2%)
Pharmaceutical Preparations; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

Customers and suppliers named in filings

Sells to

About Perrigo

Perrigo Company plc was incorporated under the laws of Ireland on June 28, 2013 and became the successor registrant of Perrigo Company, a Michigan corporation, on December 18, 2013 in connection with the acquisition of Elan Corporation, plc ("Elan"). Unless the context requires otherwise, the terms "Perrigo," the "Company," "we," "our," "us," and similar pronouns used herein refer to Perrigo Company plc, its subsidiaries, and all predecessors of Perrigo Company plc and its subsidiaries. Perrigo is a leading pure-play self-care company with more than a century of providing high-quality health and wellness solutions to meet the evolving needs of consumers.

In its own words, from its 10-K, filed Feb 26, 2026.

Perrigo against its Pharmaceutical Preparations peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -5% against the peers' median +7%. Operating margin: 2.3% against the peers' median 20.4%.

CompanyQuarterRevenueY/YOp. margin
PRGO PerrigoQ3 2026$989M-5%2.3%
JNJ Johnson & JohnsonQ3 2026$25.4B+6%0.1%
LLY ELI LillyQ3 2026$24.4B+39%34.5%
MRK MerckQ3 2026$18.1B+5%30.7%
ABBV AbbVieQ3 2026$17.4B+10%36.0%
PFE PfizerQ3 2026$16.6B-0.4%20.4%
BMY Bristol Myers SquibbQ3 2026$13.1B+7%19.4%
ABT Abbott LaboratoriesQ3 2026$13.0B+14%10.4%
REGN Regeneron PharmaceuticalsQ3 2026$5.1B+36%40.0%

Source: Perrigo 10-Q on SEC EDGAR · CIK 1585364 · Pharmaceutical Preparations

Guidance and outlook

Perrigo: what its forward-looking statements are about (10-Q filed 2026-11-04)Perrigo: what its forward-looking statements are about (10-Q filed 2026-11-04)Other8Costs4People3Financing2Demand2The economy1Capital spending1Margins1Products1Supply chain1
24 statements; tone -0.04 (−1 all cautious, +1 all confident); 6 hedged.
Perrigo: outlook statements against the filing beforePerrigo: outlook statements against the filing beforeConfident5Cautious6

More on PRGO

History

Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results

Compare PRGO with

中文版：Perrigo（PRGO）财报

Español · Français